Health and Diseases

Current GK (IBPS RRB-PO)

Title

45:30

Video Progress

8 of 24 completed

Notes Progress

5 of 15 completed

MCQs Progress

38 of 100 completed

Subjective Progress

8 of 20 completed

Continue to Next Topic

Indian Economy - Understanding the basics of Indian economic system

Next Topic

16-Aug-24

Download PDF

ICMR and Panacea Biotec begin first pivotal dengue vaccine trial in India

Panacea Biotec and the Indian Council of Medical Research (ICMR) are initiating a Phase III trial of a dengue fever vaccine.

This landmark trial (CTRI/2024/03/064910) will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll.

The virus has become a major public health concern in India, ranking it among the top 30 countries with the highest incidence of the disease.

DengiAll is based on the tetravalent dengue vaccine strain (TV003/TV005), originally developed by the National Institutes of Health (NIH) which has shown promise in previous studies.

By: Brijesh Kumar

Profile ResourcesReport error

Trial Period Ended